Retatrutide and tirzepatide are often mentioned in the same breath within metabolic research. They resemble each other but differ on one important point. In this guide we compare both molecule classes — informative and strictly research-only, without health or weight-loss claims.
Tirzepatide is a dual agonist (GIP + GLP-1) and is approved as a medicine in several countries. Retatrutide is a triple agonist that adds the glucagon receptor and is being studied in clinical trials — not approved. Peptide Lab offers Retatrutide exclusively as a research compound.
Retatrutide vs Tirzepatide: the difference
The core difference is the number of receptor targets: tirzepatide acts on two receptors, Retatrutide on three. The table below sets the key characteristics side by side.
The receptors explained
Both molecules work via GIP and GLP-1; Retatrutide adds the glucagon receptor. GLP-1 and GIP are involved in appetite, blood-sugar and fat metabolism. The glucagon receptor plays a role in energy balance. Because Retatrutide acts on all three, it is a broader object of study. Read more about the mechanism in What is Retatrutide.
Status and approval
Tirzepatide is an approved medicine; Retatrutide is still under research and is not approved. That distinction matters: the Retatrutide offered here is exclusively research material, not a medicine and not an alternative to a medicine. Peptide Lab does not sell tirzepatide.
This comparison is purely informative. At Peptide Lab, Retatrutide is intended for laboratory and research purposes — not a medicine, not a weight-loss product, not for human or animal consumption. No effect, health or weight-loss claims are made.
For research: what does this mean?
For researchers, the difference in receptor targets is the point of interest: it makes Retatrutide a broader metabolic object of study. If you work with Retatrutide, always check the purity and batch number — read how to read a COA. See the Retatrutide product page or the category Fat loss & metabolism.
Frequently asked questions about Retatrutide and Tirzepatide
What is the difference between Retatrutide and Tirzepatide?
Tirzepatide is a dual agonist that acts on two receptors (GIP and GLP-1). Retatrutide is a triple agonist and adds a third target: the glucagon receptor. The key difference is therefore the number of receptor targets.
Is Retatrutide stronger than Tirzepatide?
Retatrutide targets more receptors, but 'stronger' is not a meaningful statement outside a specific research context. Both are studied in research; no effect or performance comparisons for human use are made here.
Is Tirzepatide approved?
Tirzepatide is approved as a medicine in several countries. Peptide Lab does not sell Tirzepatide as a medicine; the comparison is purely informative.
Is Retatrutide approved?
No. Retatrutide is being studied in clinical trials but is not approved as a medicine. At Peptide Lab it is exclusively a research compound.
Can I buy Retatrutide for research?
Yes, Retatrutide is available at Peptide Lab as a research compound, lab-verified at ≥99% purity and exclusively for laboratory and research purposes.
Sources & further reading
Independent third-party references — for further reading, not an endorsement or partnership.
- Dr. Peter Attia, MD — Scientific analyses of longevity and a critical view of peptide and hormone hype
